Natural Killer Cell Therapy

also known as NK cell therapy

Developed for: myelodysplastic syndrome · plasma cell myeloma · chronic lymphocytic leukemia/small lymphocytic lymphoma · glioblastoma · Hodgkins lymphoma · leukemia, myeloid, accelerated-phase · therapy related acute myeloid leukemia and myelodysplastic syndrome · acute biphenotypic leukemia
+18 more
· acute myeloid leukemia · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · acute myeloid leukemia with t(8;21)(q22;q22) translocation · adult T-cell leukemia/lymphoma · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · childhood medulloblastoma · chronic myeloid leukemia · diffuse large B-cell lymphoma · ependymoma · high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement · leukemia · mantle cell lymphoma · nodular basal cell carcinoma · plasma cell leukemia · primary cutaneous T-cell lymphoma · skin squamous cell carcinoma · Waldenstrom macroglobulinemia
Investigated by: National Cancer Institute (NCI) · M.D. Anderson Cancer Center · Fred Hutchinson Cancer Center · John Reneau · Marzieh Ebrahimi · National Institute of Allergy and Infectious Diseases (NIAID)
+5 more
· Ohio State University Comprehensive Cancer Center · Royan Institute · Sumithira Vasu · Tehran University of Medical Sciences · The Wayne D. Kuni and Joan E. Kuni Foundation

Trials 11 · a red edge is where a trial was stopped

today NCT07144384 · Ph 0 NCT06687681 · Ph 2 NCT04848064 · Ph 1 NCT05108012 · Ph 1 NCT02316964 · Ph 1 NCT02271711 · Ph 1 NCT01904136 · Ph 1/2 NCT01729091 · Ph 2 NCT01619761 · Ph 1 NCT00789776 · Ph 1/2 NCT00450983 · Ph 2

200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT07144384	Oct 2025 → Apr 2026 overdue	nodular basal cell carcinoma, skin squamous cell carcinoma	Ohio State University Comprehensive Cancer Center	Active not recruiting	No outcome recorded
Phase 15 trials
Phase 1	NCT04848064	May 2022 → Oct 2026 expected	adult T-cell leukemia/lymphoma, primary cutaneous T-cell lymphoma	John Reneau	Recruiting	No outcome recorded
Phase 1	NCT05108012	Aug → Nov 2021	glioblastoma	Royan Institute	Unknown	No outcome recorded
Phase 1	NCT02316964	Apr 2015 → Dec 2017	acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22), acute myeloid leukemia with t(8;21)(q22;q22) translocation	Sumithira Vasu	Completed	No outcome recorded
Phase 1	NCT02271711	Mar 2015 → Aug 2020	childhood medulloblastoma, ependymoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1	NCT01619761	May 2013 → Nov 2021	Hodgkins lymphoma, acute biphenotypic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement +4	M.D. Anderson Cancer Center	Unknown	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT01904136	Apr 2014 → Feb 2022	blast phase chronic myelogenous leukemia, BCR-ABL1 positive, leukemia, myeloid, accelerated-phase, myelodysplastic syndrome, therapy related acute myeloid leukemia and myelodysplastic syndrome	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00789776	Oct 2008 → May 2017	Hodgkins lymphoma, Waldenstrom macroglobulinemia, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +5	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 23 trials
Phase 2	NCT06687681	Nov 2024 → Nov 2025 overdue	glioblastoma	Marzieh Ebrahimi	Recruiting	No outcome recorded
Phase 2	NCT01729091	Jun 2013 → Jun 2024	plasma cell leukemia, plasma cell myeloma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00450983	Dec 2006 → Jul 2010	graft versus host disease, leukemia, myelodysplastic syndrome	Fred Hutchinson Cancer Center	Terminated	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT02259348 Background	Oct 2014 → Apr 2015	acute lymphoblastic leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome +1	St. Jude Children's Research Hospital	Terminated	No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

Field	Value	Cited text
Known as	Natural Killer Cell Therapy	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01904136 ↗ 9 NCT01619761 ↗ NCT04848064 ↗ NCT00789776 ↗ NCT02316964 ↗ NCT02271711 ↗ NCT07144384 ↗ NCT01729091 ↗ NCT00450983 ↗ NCT02259348 ↗
Known as	NK cell therapy	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05108012 ↗ 1 NCT06687681 ↗
Action	Deplete	“Giving third-party natural killer cells in combination with mogamulizumab may kill more cancer cells.” NCT04848064 ↗
Modality	Cell therapy	“donor natural killer cell transplant” NCT00450983 ↗
Route	Intravenous	“Given IV” NCT00789776 ↗